East African follow-up data show GSK malaria vaccine efficacy is sustained
This article was originally published in Scrip
GlaxoSmithKline's RTS,S/AS01E candidate recombinant malaria vaccine showed both significant efficacy and sustained activity in an eight to15 months follow up study of nearly 900 children in Kenya and Tanzania, according to a paper published online on 14 January in The Lancet Infectious Diseases.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.